QURE - Why UniQure Stock Is Soaring | Benzinga
UniQure N.V. (NASDAQ:QURE) shares are trading higher Tuesday after the company announced updated interim data from its ongoing U.S. and European Phase I/II clinical trials of AMT-130 for the treatment of Huntington’s disease.
The Details:
UniQure said a statistically significant, dose-dependent, slowing in disease progression measured by cUHDRS was observed through 24 months in patients receiving the high dose of AMT-130. The company also said it observed a statistically significant reduction of NfL in cerebrospinal fluid (CSF) in patients treated with AMT-130.
Read Next: What Happened With Trump Media & Technology Group Stock Today?
“We are very pleased with these new data demonstrating a statistically significant, dose-dependent slowing of the progression of Huntington’s disease and lowering of NfL in the CSF at 24 months,” stated Walid Abi-Saab, M.D., chief medical officer of UniQure.
“We ...